JD Supra

Federal Court finds patent for concentrated methotrexate solutions obvious

On March 26, 2024, the Federal Court dismissed Medexus and Medac’s action for patent infringement of Canadian Patent No 2,659,662 (the 662 Patent), finding the asserted claims invalid for obviousness: ...
Healio

FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents ...
Becker's Hospital Review

Accord Healthcare resumes making methotrexate

Accord Healthcare, a London-based drugmaker, resumed manufacturing of two methotrexate solutions, according to a Nov. 7 update from the FDA. By March, the American Society of Health-System Pharmacists ...
Eagle-Tribune

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO ™ (methotrexate) to ...